Deborah Jean Pedersen, MD
Allergy & Immunology · Taunton, MANPI 1023281532
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.2%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 63.4% of it on its own, with 18 other manufacturers making up the rest. 2025 is the largest year on record at $4,836, more than ten times the $31 reported in 2019.
Across 97 payments — averaging $68.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Invivyd Inc$1K
- Blueprint Medicines Corporation$130
- Pfizer$128
- Regeneron Healthcare Solutions, Inc.$121
- GC Biopharma USA, Inc.$106
- plus $481 from 13 others
What the payments were for
- Consulting fees$1,45322%
- Speaking & faculty fees$2,92344%
- Travel & lodging$70%
- Food & beverage$2,22434%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 60 | $4,187 |
| Invivyd Inc | 1 | $1,453 |
| Blueprint Medicines Corporation | 3 | $130 |
| Pfizer | 6 | $128 |
| Regeneron Healthcare Solutions, Inc. | 1 | $121 |
| GC Biopharma USA, Inc. | 4 | $106 |
| Kedrion Biopharma, Inc. | 3 | $71 |
| GSK | 4 | $69 |
| Regeneron | 1 | $68 |
| Sanofi | 2 | $55 |
| Pharming Healthcare, Inc. | 2 | $42 |
| Grifols USA, LLC | 2 | $37 |
| Amgen | 1 | $32 |
| Genentech USA, Inc. | 2 | $31 |
| Octapharma USA, Inc. | 1 | $22 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $14 |
| CSL Behring | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| LEO Pharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,606 in reported general payments places this provider in the 60th percentile of 114 allergy & immunology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 53 | $234,102 |
| Dupixent SyringeDupilumab | 42 | $212,387 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 13 | $82,912 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $38,967 |
| Breo ElliptaFluticasone/Vilanterol | 48 | $27,031 |
| Spiriva RespimatTiotropium Bromide | 24 | $23,015 |
| Advair HfaFluticasone Propion/Salmeterol | 25 | $15,132 |
| SymbicortBudesonide/Formoterol Fumarate | 31 | $11,360 |
| Arnuity ElliptaFluticasone Furoate | 27 | $7,641 |
| Incruse ElliptaUmeclidinium Bromide | 15 | $7,578 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 27 | $5,966 |
| Epinephrine | 40 | $5,776 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 163 | $5,461 |
| Wixela InhubFluticasone Propion/Salmeterol | 22 | $2,563 |
| Ventolin HfaAlbuterol Sulfate | 29 | $2,387 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam | $128 | $82,91213 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $69 | $81,217140 claims |
| AstraZenecaSymbicort | $4,187 | $11,36031 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 114 allergy & immunology providers in Massachusetts.
Other allergy & immunology in Taunton
- Wanda PhipatanakulBoston$679K
- Jonathan BayukNorthampton$420K
- Kathleen BuchheitBoston$224K
- Francisco BonillaLeominster$188K
- Aleena BanerjiBoston$133K
- Margo StevensonSturbridge$98K
- Jeffrey GelfandBoston$84K
- Paul MaglioneBoston$66K
- Maria CastellsGardner$65K
- Ami MehraChelmsford$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.